Full Service Pharmaceutical R&D

We are experts at formulation development, analytical method development, manufacturing process development and tech transfer, CRO management for BE studies, CMC regulatory documentation, and regulatory filings

ABOUT Vici

Vici delivers end-to-end drug development solutions for small pharma. We provide formulation development, analytical method validation and testing, cGMP clinical supplies manufacturing, FDA regulatory services, and CMC R&D consulting services. We are experts in NCE molecule development, NDA 505(b)(2), and ANDA development programs. Our experienced formulation scientists and chemists solve problems through innovation, speed, and flexibility offering excellent value for companies needing better R&D outcomes. Vici operates a pharmaceutical R&D center of excellence in Maryland, USA.

OUR VALUES

CUSTOMER FOCUS

We believe in building lasting relationships with our customers, and each employee is committed to integrity and diligence to promote growth and understanding.

EXCELLENCE IN R&D

We differentiate ourselves from other CDMOs by being an R&D focused company, dedicated to science and innovation. We pride ourselves on delivering results with quality and speed .

INNOVATIVE MINDSET

We focus on constantly evolving our business to best fit our customers needs and stay at the forefront of pharmaceutical research and development.

LEADERSHIP

ANISH DHANARAJAN, Ph.D.

CEO

Dr. Anish Dhanarajan has over 20 years of experience as a scientist and is a leader in the pharmaceutical industry. After completing his PhD in Biomedical/Chemical Engineering with a focus on drug delivery at the University of Minnesota, he started his pharmaceutical industry career as an industrial postdoc at Pfizer, Michigan, developing mathematical and experimental methodologies for scaling up pharmaceutical manufacturing processes. Subsequently, he worked as a formulation scientist developing complex, controlled-release dosage forms.

After gaining experience as a scientist and leader at various companies including Mallinckrodt, CorePharma, and GSK, Anish co-founded Vici Health Sciences. As the CEO of Vici Health Sciences, Anish successfully selected and developed NDA and ANDA drug products for licensing, resulting in the commercialization of multiple pharmaceutical products. Currently, he is focused on developing Vici as an R&D center of excellence committed to providing world class end-to-end drug development and manufacturing services to other startups and small pharma.

FRANCESCA MINALE, M.ENG.

President

Francesca Minale is a well-rounded, experienced pharmaceutical product development expert with a broad understanding of formulations, analytical chemistry, regulatory requirements, and cGMP concepts.

As a tireless manager and scientist, Francesca has developed and filed over 20 products, authored multiple patents, and been responsible for over a dozen successful INDs to initiate Phase I and Phase II clinical studies. Francesca co-founded Vici with Dr. Dhanarajan and has successfully managed day-to-day operations, regulatory filings, and quality assurance.

Francesca Minale holds a Master’s degree in Biomedical Engineering at Cornell University and has over 13 years’ experience at CorePharma, WES Pharma and at Vici. Francesca is passionate about affordable housing and is involved in a variety of non-profit initiatives related to affordable housing and homelessness in the Baltimore area. In her free time, Francesca enjoys redesigning and renovating homes in need of repair to improve communities and neighborhoods.

SUNEEL RASTOGI, Ph.D.

Senior Director, Product Development

Dr. Suneel Rastogi brings in over 24 years of extensive experience in the development of a variety of conventional and complex dosage forms including oral dosage forms, injectables, long acting, amorphous solid dispersions, ophthalmic, topical, nano particulates, peptides, nasal sprays and rectal gels.

He has a proven track record of successfully managing over 100 internal and external development projects including several challenging high value blockbuster brand as well as generic products. In addition, he has led the technical due diligence evaluation on over 150 products for acquisition, in-licensing and co-development. He has authored numerous patents and publications in the areas of drug delivery, pharmaceutical applications of particle engineering, pharmaceutical characterization, solid state reactions and phase transitions, X-ray powder diffractometry, atomic layer deposition, novel technology development and protein stabilization.

Dr. Rastogi has a PhD in Pharmaceutical Science from the University of Minnesota and has held previous scientific and leadership positions at Forest Labs, Mallinckrodt, Impax, Leading Pharma, and Applied Materials.

ANNA RAZYNSKA, Ph.D.

Senior R&D Advisor

Dr Anna Razynska is a Research & Development expert with extensive experience in chemical, biochemical, organic, and analytical chemistry within the pharmaceutical industry. She has a successful track record in analytical R&D, method validation, process improvement, and quality assurance, CMC documentation of FDA filings and cGMP compliance regulations.

Anna has successfully led teams and supervised contract laboratories in the development and testing of different drug products including solids, semi-solids and liquids for successful FDA approvals and project deliverables. Through her years in academia and industry, Anna has developed and demonstrated excellent leadership, creative technical solutions, analytical and problem resolution skills.

Dr. Razynska has a PhD in Organic Chemistry from the University of Gdansk and has held scientific positions and managerial positions at Actavis, Alpharma, Purdue Pharma, and the University of Maryland Medical Center. Anna brings her love for teaching to her job and enjoys mentoring and grooming junior talent in various organizations.